SCHEMBL3307688

SCHEMBL3307688

Fc1cc(-c2ccc3scnc3c2)cc(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
RXRG P48443 1/20 0.42
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
DYRK1A Q13627 1/20 0.39
PGR P06401 1/20 0.38
RIPK2 O43353 7/20 0.37
KDR P35968 3/20 0.37
TGFBR1 P36897 3/20 0.37
EGFR P00533 1/20 0.37
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
FFAR1 O14842 1/20 0.36
LCK P06239 2/20 0.36
FASN P49327 1/20 0.36
PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3311489 0.86 DYRK1A (0.46) ALOX5APFEN1DYRK1ARIPK2KDR
SCHEMBL3305165 0.80 CYP11B2 (0.47) ALOX5APFEN1DYRK1ARIPK2KDR
SCHEMBL1850000 0.79 HSD17B1 (0.43) ALOX5APFEN1DYRK1ARIPK2KDR
SCHEMBL28048502 0.78 ALDH1A1 (0.54) ALOX5APFEN1DYRK1ARIPK2KDR
SCHEMBL1851823 0.77 KIF11 (0.49) ALOX5APFEN1
SCHEMBL3307500 0.77 MPL (0.48) ALOX5APFEN1DYRK1ARIPK2KDR
SCHEMBL1538312 0.76 NPC1 (0.47) DYRK1AMEN1NPC1POLBRAB9A
SCHEMBL30375905 0.76 NPC1 (0.47) DYRK1AMEN1NPC1POLBRAB9A
SCHEMBL3306486 0.75 ALOX5AP (0.39) ALOX5APFEN1DYRK1ARIPK2KDR
SCHEMBL3306723 0.75 CYP11B1 (0.44) ALOX5APFEN1DYRK1ARIPK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology APP, APBA1, PYGB RXRA 3772/4885RXRB 3041/4885RXRG 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.